Better glycaemic control for 30,171 insulin-naive patients with type 2 diabetes after starting biphasic insulin aspart 30/70 (BIAsp 30) therapy:: IMPROVE™ study subgroup analysis

被引：0
|
作者：
Kawamori, R. [1 ]
Srishyla, M. V. [2 ]
Wenying, Y. [3 ]
机构：
[1] Juntendo Univ, Sch Med, Dept Metab & Endocrinol, Tokyo 113, Japan
[2] Novo Nordisk AS, Virum, Denmark
[3] China Japan Friendship Hosp, Dept Endocrinol, Beijing, Peoples R China
来源：
DIABETOLOGIA | 2008年 / 51卷
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
978
引用
收藏
页码：S393 / S394
页数：2
相关论文
共 50 条
  • [41] Effect of biphasic insulin aspart 30 combined with metformin on glycaemic control in obese people with type 2 diabetes
    Ascic-Buturovic, Belma
    BOSNIAN JOURNAL OF BASIC MEDICAL SCIENCES, 2007, 7 (04) : 335 - 338
  • [42] Safety and effectiveness of biphasic insulin aspart 30/70 (NovoMix® 30) when switching from human premix insulin in patients with type 2 diabetes: subgroup analysis from the 6-month IMPROVE™ observational study
    Shah, S.
    Benroubi, M.
    Borzi, V.
    Gumprecht, J.
    Kawamori, R.
    Shaban, J.
    Shestakova, M.
    Wenying, Y.
    Valensi, P.
    INTERNATIONAL JOURNAL OF CLINICAL PRACTICE, 2009, 63 (04) : 574 - 582
  • [43] Hypoglycaemia events with iGlarLixi versus premix biphasic insulin aspart 30 (BIAsp 30) in people with type 2 diabetes advancing from basal insulin: An analysis of the SoliMix trial
    McCrimmon, Rory J.
    Home, Philip
    Cheng, Alice
    Giorgino, Francesco
    Fonseca, Vivian
    Souhami, Elisabeth
    Alvarez, Agustina
    Picard, Pascaline
    Rosenstock, Julio
    DIABETES OBESITY & METABOLISM, 2022, 24 (12): : 2391 - 2399
  • [44] Patients with Type 2 diabetes mellitus have lower rates of nocturnal hypoglycaemia on biphasic insulin aspart (BIAsp30) than on biphasic human insulin-30 (BHI30): data from the REACH study
    McNally, PG
    Nelson, G
    Fitch, M
    DIABETOLOGIA, 2004, 47 : A327 - A327
  • [45] Switching to biphasic insulin aspart 30/50/70 from biphasic human insulin 30/50 in patients with type 2 diabetes in normal clinical practice: observational study results
    Nobels, Frank
    D'Hooge, Dirk
    Crenier, Laurent
    CURRENT MEDICAL RESEARCH AND OPINION, 2012, 28 (06) : 1017 - 1026
  • [46] Cost-effectiveness analysis of insulin therapy in type 2 diabetes patients comparing biphasic insulin aspart 70/30 versus insulin plargine in the Swedish setting
    Ray, Joshua A.
    Munro, Vicki
    Brandt, Ann-Sofie
    Valentine, William J.
    Roze, Stephane
    Foos, Volker
    Lurati, Francesco
    Palmer, Andrew J.
    DIABETES, 2006, 55 : A558 - A558
  • [47] Comparison of twice-daily biphasic insulin aspart 70/30 (BIAsp 70/30) with once-daily insulin glargine (GLA) in patients with type 2 DM on oral antidiabetic agents
    Raskin, P
    Rojas, P
    Allen, E
    DIABETES, 2004, 53 : A143 - A143
  • [48] A comparison of pharmocodynamics and pharmacokinetics of Biphasic Insulin Aspart 30, 50, 70 & Pure Insulin Aspart in type 1 diabetes
    Thorisdottir, Rannveig L.
    Parkner, Tina
    Chen, Jian-Wen
    Ejskjaer, Niels
    Christiansen, Jens S.
    DIABETES, 2007, 56 : A555 - A555
  • [49] COST-EFFECTIVENESS OF INSULIN DEGLUDEC/INSULIN ASPART (IDEGASP) COMPARED WITH BIPHASIC INSULIN ASPART (BIASP 30) IN PATIENTS WITH TYPE 2 DIABETES MELLITUS FROM A MEXICAN HEALTHCARE PERSPECTIVE
    Sanchez-Pedraza, V
    Hansen, B. B.
    Gundgaard, J.
    Uranga Romano, Garca J.
    Evans, M.
    VALUE IN HEALTH, 2016, 19 (07) : A672 - A672
  • [50] The safety and efficacy of biphasic insulin aspart 30 (BIAsp 30) in Iranians with type 2 diabetes: an open-label, non-randomised, multi-centre observational study - the Iran subgroup of the IMPROVE™ study
    Esteghamati, Alireza
    Rajabian, Reza
    Amini, Masoud
    Bahrami, Amir
    Khamseh, Mohammad Ebrahim
    Afkhami-Ardekani, Mohammad
    Rizi, Ehsan Parvaresh
    ENDOKRYNOLOGIA POLSKA, 2010, 61 (04) : 364 - 370
12345